Moreover, transcriptomic data on MBC showed that male breast tumors associated with germline BRCA1/2 PVs and those with a high immune involvement were also characterized by a high HER2 signaling score, despite being classified as HER2-negative by IHC, suggesting that the HER2 pathway may be active [32,33,34]; thus, they might benefit from treatment with T-DXd, or from a combined therapeutic approach including PARPi and/or immunotherapy. This evidence concerns the gene BRCA1 and breast neoplasm.